「th」の検索結果
188件：86～90件目を表示
-
harmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida) today announces that it has received approval for the marketing of “Mytear Lumify” (OTC drug requiring instruction b...
https://www.senju.co.jp/system/files/content_news/2024-08/ENG_20240903_0.pdf -
Presence of Products | Overseas Activities | SENJU Pharmaceutical
Asia Middle East Europe North&South Ameica Asia India Brand Name Marketing Authorisation Holder JP Brand Name GLUCOTIM－LA Centaur Pharmaceuticals PVT LTD Not marketed in JP Korea Brand Name Market...
http://www.senju.co.jp/english/global/world.html -
发表论文 | 研究与开发 | 千寿制药株式会社
媛大学医学部眼科学教室 2)千寿製薬株式会社 3)日野病院 あたらしい眼科42(12)：1566～1576 Efficacy and Safety of SJP-0132 in Patients with Dry Eye Disease: A Phase 2b Randomized, Double-Masked, Dose-Finding Study Yuichi Hori1, Tomoyuki ...
http://www.senju.co.jp/chinese/rd/thesis/ -
千寿製薬株式会社
p; RELEASE December 22, 2025 Obtained manufacturing and marketing approval in Japan for Avarept® Ophthalmic suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Receptor Potential c...
http://www.senju.co.jp/english/ -
harmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida) today announces that it has received approval for the marketing of “Mytear Lumify” (OTC drug requiring instruction b...
https://www.senju.co.jp/system/files/content_news/2024-08/ENG_20240903.pdf